<DOC>
	<DOC>NCT02704507</DOC>
	<brief_summary>A randomized, split-face, placebo-controlled, double-blind, single-center clinical trial comparing topical retinoid on half the face and retinoid plus topical steroid on the other half.</brief_summary>
	<brief_title>Addition of a Topical Steroid to a Topical Retinoid in Acne Patients</brief_title>
	<detailed_description>A randomized, split-face, placebo-controlled, double-blind, single-center clinical trial wherein 20 patients received daily 0.05% tretinoin with one half of the face receiving triamcinolone 0.025% and the other half an inert emollient for 4 weeks. Subjects continued applying tretinoin 0.05% daily to the bilateral face without triamcinolone or emollient for an additional 4 weeks. Investigator's Global Assessment, lesion counts, and study subject's self-assessments of burning/stinging, itching, erythema, and dryness/scaling will be collected at 1, 2, 4, and 8 weeks.</detailed_description>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Emollients</mesh_term>
	<criteria>Fitzpatrick skin types I, II, or III Will and ability to discontinue use of topical medicines on the face for study duration Capability to understand and provide informed consent Use of oral retinoids within previous 6 months Use of corticosteroids on the face or systemic corticosteroids within previous 4 weeks Any additional facial skin condition (i.e., rosacea, seborrheic dermatitis, etc.) Female participants who are pregnant, nursing, or planning pregnancy while participating in the study Hypersensitivity to ingredients in study formulations Existence of an underlying condition that an investigator feels would hinder a participant's ability to complete the study or appropriately follow directions</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>tretinoin</keyword>
	<keyword>topical steroid</keyword>
	<keyword>irritation</keyword>
	<keyword>retinoid induced irritation</keyword>
</DOC>